Triple-negative breast cancer (TNBC), characterized by absent or minimal expression of hormone receptor [estrogen receptor (ER) and progesterone receptor (PR)] and human epidermal growth factor receptor 2 (HER2), constitutes 10%–20% of all breast cancers [1–3]. Here, ERBB2 is linked to triple-negative breast carcinoma.